Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials
Authors
Keywords
-
Journal
Open Forum Infectious Diseases
Volume 4, Issue 2, Pages -
Publisher
Oxford University Press (OUP)
Online
2017-06-01
DOI
10.1093/ofid/ofx063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- New Societal Approaches to Empowering Antibiotic Stewardship
- (2016) Brad Spellberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain
- (2016) Zaira R. Palacios-Baena et al. JOURNAL OF INFECTION
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience
- (2015) James A. McKinnell et al. CLINICAL INFECTIOUS DISEASES
- Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study
- (2015) D.R. Giacobbe et al. CLINICAL MICROBIOLOGY AND INFECTION
- Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
- (2015) Mario Tumbarello et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae
- (2014) Mario Tumbarello et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
- (2014) George L. Daikos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations
- (2014) S Nambiar et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence
- (2013) Matthew E. Falagas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Predictors of mortality in multidrug-resistantKlebsiella pneumoniaebloodstream infections
- (2013) Pierluigi Viale et al. Expert Review of Anti-Infective Therapy
- A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
- (2013) John H Rex et al. LANCET INFECTIOUS DISEASES
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- (2013) L Silvia Munoz-Price et al. LANCET INFECTIOUS DISEASES
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
- (2012) Zubair A. Qureshi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
- (2012) M. Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: A matched case-control study
- (2011) Shi-Wei Liu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Challenges in Anti‐Infective Development in the Era of Bad Bugs, No Drugs: A Regulatory Perspective Using the Example of Bloodstream Infection as an Indication
- (2010) Helen W. Boucher CLINICAL INFECTIOUS DISEASES
- Prospective Observational Study of the Impact of VIM-1 Metallo- -Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections
- (2009) G. L. Daikos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
- (2008) Helen W. Boucher et al. CLINICAL INFECTIOUS DISEASES
- Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies
- (2008) Gopi Patel et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More